Phase II Trial of Pemetrexed Plus Bevacizumab for Second-Line Therapy of Patients With Advanced Non–Small-Cell Lung Cancer: NCCTG and SWOG Study N0426

PURPOSE: To evaluate the efficacy and toxicity of pemetrexed combined with bevacizumab as second-line therapy for patients with advanced non–small-cell lung cancer (NSCLC) and to correlate allelic variants in pemetrexed-metabolizing genes with clinical outcome. PATIENTS AND METHODS: Patients with pr...

詳細記述

保存先:
書誌詳細
主要な著者: Adjei, Alex A., Mandrekar, Sumithra J., Dy, Grace K., Molina, Julian R., Adjei, Araba A., Gandara, David R., Ziegler, Katie L. Allen, Stella, Philip J., Rowland, Kendrith M., Schild, Steven E., Zinner, Ralph G.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2010
主題:
Original Reports
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2815996/
https://ncbi.nlm.nih.gov/pubmed/19841321
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.23.6406
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料